{"id":"mosunetuzumab-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bispecific T-cell engager (BiTE), mosunetuzumab bridges cytotoxic T lymphocytes to CD20-expressing malignant B cells, bringing them into close proximity to facilitate T cell-mediated destruction of lymphoma cells. This dual-targeting approach leverages the patient's own immune system to eliminate tumor cells while potentially reducing systemic toxicity compared to traditional chemotherapy.","oneSentence":"Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:08.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT06337318","phase":"PHASE3","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-23","conditions":"Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features","enrollment":600},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT04246086","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-12","conditions":"Follicular Lymphoma","enrollment":237},{"nctId":"NCT04970901","phase":"PHASE1","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","status":"RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-17","conditions":"B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT05207670","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-02-01","conditions":"Non-Hodgkin Lymphoma","enrollment":320},{"nctId":"NCT05091424","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":137},{"nctId":"NCT06594939","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":31},{"nctId":"NCT06492837","phase":"PHASE2","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-10-23","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT05389293","phase":"PHASE2","title":"A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-27","conditions":"Follicular Lymphoma, Lymphoma","enrollment":152},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT06569680","phase":"PHASE2","title":"Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Izidore Lossos, MD","startDate":"2024-11-19","conditions":"Extranodal Marginal Zone Lymphoma","enrollment":35},{"nctId":"NCT07191249","phase":"PHASE2","title":"A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2025-10-10","conditions":"Follicular Lymphoma","enrollment":30},{"nctId":"NCT06453044","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-09-09","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma","enrollment":41},{"nctId":"NCT02500407","phase":"PHASE1, PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-09-15","conditions":"Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin","enrollment":713},{"nctId":"NCT03677154","phase":"PHASE1, PHASE2","title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":188},{"nctId":"NCT05155345","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-01-11","conditions":"Systemic Lupus Erythematosus","enrollment":15},{"nctId":"NCT05169658","phase":"PHASE2","title":"Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2022-03-23","conditions":"Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma","enrollment":42},{"nctId":"NCT05994235","phase":"PHASE2","title":"Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-11-01","conditions":"Follicular Lymphoma","enrollment":50},{"nctId":"NCT03671018","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-25","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":422},{"nctId":"NCT06284122","phase":"PHASE3","title":"Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2024-06-07","conditions":"Follicular Lymphoma","enrollment":790},{"nctId":"NCT05315713","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-10","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":8},{"nctId":"NCT05849857","phase":"PHASE2","title":"Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2023-09-11","conditions":"Lymphoma, Follicular","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mosunetuzumab","RO7030816"],"phase":"phase_3","status":"active","brandName":"Mosunetuzumab (SC)","genericName":"Mosunetuzumab (SC)","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}